Trade Mark Journal No.2024/050 13 December 2024

WO0000001824729 (5,10)

Office of origin: United States of America

Date of International Registration:6 August 2024
Date of designation in the UK: 6 August 2024
Image for mark 1824729 DURASERT E

International priority date claimed: 21 February 2024 (Canada) (2311388)
International priority date claimed: 1 August 2024 (United States of America) (98677791)
Class 5
Injectable pharmaceutical preparations comprising erodible ingredients that facilitate the delivery of pharmaceuticals via injection into the posterior segment of the eye for the treatment of eye diseases and conditions of the retina, namely, wet age-related macular degeneration, non-proliferative diabetic retinopathy, diabetic macular edema and retinal vein occlusion and excluding dry eye, conjunctivitis, glaucoma and bacterial eye infections.
Class 10
Injectable sustained drug delivery systems for delivering pharmaceuticals via injection into the posterior segment of the eye.

EyePoint Pharmaceuticals US, Inc.